Farmakoterapia w Psychiatrii i Neurologii

Pełna treść

1/2024 vol. 40
Opis przypadku

Indywidualizacja leczenia stwardnienia rozsianego – opis przypadku

Gabriela Trojan 1
,
Krzysztof Nadgrodkiewicz 2
  1. Studenckie Koło Naukowe „Neurologia”, Uniwersytet Technologiczno-Humanistyczny im. Kazimierza Pułaskiego w Radomiu, Radom, Polska; Kazimierz Pulaski University of Technology and Humanities in Radom, Radom, Poland
  2. Klinika Neurologii, Mazowiecki Szpital Specjalistyczny w Radomiu, Radom, Polska; Neurology Clinic, Masovian Specialist Hospital in Radom, Radom, Poland
Farmakoterapia w Psychiatrii i Neurologii 2024, 40 (1), 61–68
DOI: https://doi.org/10.5114/fpn.2024.140240
Data publikacji online: 2024/08/01
Plik artykułu
07_IPiN_FARM_2024-1C_Individualization of multiple sclerosis treatment.pdf
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease
  1. Adamczyk B. Najnowsze spojrzenie na immunopatologię stwardnienia rozsianego. https://www.mp.pl/sm/przeglad-badan/336002,najnowsze-spojrzenie-na-immunopatologie-stwardnienia-rozsianego (dostęp 27 listopada 2023).
  2. Adamczyk-Sowa M, Adamczyk B, Kułakowska A, Rejdak K, Nowacki P. Secondary progressive multiple sclerosis – from neuropathology to definition and effective treatment. Neurol Neurochir Pol 2020; 54 (5): 384-98.
  3. Bourgault C, Mcgregor M, Barkun J, Brodie W, Brophy J, Johnston J et al. REPORT NUMBER 3. Muhc.ca. Published 2002. (dostęp 27 listopada 2023) https://muhc.ca/sites/default/files/micro/m-TAU/Mitoxantrone.pdf.
  4. Brola W, Sobolewski P, Flaga S, Fudala M, Szczuchniak W, Stoiński J et al. Prevalence and incidence of multiple sclerosis in central Poland, 2010–2014. BMC Neurol. 2016; 16 (1): 134.
  5. Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA 2019; 321 (2): 175.
  6. Butzkueven H, Kappos L, Wiendl H, Trojano M, Spelman T, Chang I et al. Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP). J Neurol Neurosurg Psychiatry 2020; 91 (6): 660-8.
  7. Coyle PK. What can we learn from sex differences in MS? J Pers Med. 2021; 11(10): 1006.
  8. Cross A, Riley C. Treatment of multiple sclerosis. Continuum (Minneap Minn). 2022; 28 (4): 1025-1051.
  9. Dayama A, Bhargava R, Kurmi S, Jain S, Dua V. Autologous stem cell transplant in adult multiple sclerosis patients: A study from North India. Neurol India 2020; 68 (2): 454.
  10. Dymecka J, Gerymski RJ. Niepełnosprawność a jakość życia pacjentów ze stwardnieniem rozsianym: mediacyjna rola zapotrzebowania na wsparcie społeczne. Człowiek Niepełnosprawność Społeczeństwo 2019; 46: 63-78.
  11. Edan G, Le Page E. Induction therapy for patients with multiple sclerosis: Why? When? How? CNS Drugs 2013; 27 (6): 403-9.
  12. Lefort M, Le Corre G, Le Page E, Rizzato C, Le Port D, Michel L et al. Ten-year follow-up after mitoxantrone induction for early highly active relapsing-remitting multiple sclerosis: An observational study of 100 consecutive patients. Rev Neurol (Paris) 2022; 178 (6): 569-79.
  13. Morrow SA, Clift F, Devonshire V, Lapointe E, Schneider R, Stefanelli M et al. Use of natalizumab in persons with multiple sclerosis: 2022 update. Mult Scler Relat Disord 2022; 65 (103995): 103995.
  14. Muraro PA, Pasquini M, Atkins HL, Bowen JD, Farge D, Fassas A et al. Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis. JAMA Neurol 2017; 74 (4): 459.
  15. Ruggieri S, Pontecorvo S, Tortorella C, Gasperini C. Induction treatment strategy in multiple sclerosis: a review of past experiences and future perspectives. Mult Scler Demyelinating Disord 2018; 3 (1).
  16. Rush CA, MacLean HJ, Freedman MS. Aggressive multiple sclerosis: proposed definition and treatment algorithm. Nat Rev Neurol 2015; 11 (7): 379-89.
  17. Scott LJ, Figgitt DP. Mitoxantrone: A Review of its Use in Multiple Sclerosis. CNS Drugs 2004; 18 (6): 379-96.
  18. Szwed M. Mitoksantron – antybiotyk antrachinonowy. Postepy Hig Med Dosw 2014; 68: 198-208.
  19. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018; 17 (2): 162-73.
  20. Tur C, Carbonell-Mirabent P, Cobo-Calvo Á, Otero-Romero S, Arrambide G, Midaglia L et al. Association of early progression independent of relapse activity with long-term disability after a first demyelinating event in multiple sclerosis. JAMA Neurol. 2023; 80 (2): 151.
  21. Wnuk M, Maluchnik M, Perwieniec J, Podwojcic K, Szelag M, Walkiewicz D et al. Multiple sclerosis incidence and prevalence in Poland: Data from administrative health claims. Mult Scler Relat Disord 2021; 55 (103162): 103162.
ZGŁASZANIE PRAC
Udostępnij
without publication fees
without publication fees
Zintergrowane z
Zasady redakcyjne
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications